bifidobacterium rhamnosus

Cell therapyexperimental

Clinical trial activity

7 trials · 13 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2001 (NCT00224432)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • microbiotaTissue restoration

    microbiota tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • bifidobacterium rhamnosus

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04246151Early Phase 1 (Phase 1)Mar 31, 2020Hamilton Health Sciences Corporation
NCT03928587N/AMay 1, 2019Chr Hansen, University of Copenhagen
NCT03798821N/AJan 8, 2018Universidad Católica San Antonio de Murcia
NCT03530501N/AAug 29, 2016Government of Spain, University of Malaga
NCT03657485N/AApr 30, 2014Jagiellonian University
NCT01479543N/ANov 30, 2011Hero Institute for Infant Nutrition, Universidad de Murcia, University of Granada, University of Valencia
NCT00224432N/AMar 1, 2001Numico Research, University of Groningen
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Chr HansenFor profit1112019
Government of SpainGovernment1112016
Hamilton Health Sciences CorporationAcademic/Hospital1112020
Hero Institute for Infant NutritionAcademic/Hospital1112011
Jagiellonian UniversityAcademic/Hospital1112014
Numico ResearchFor profit1012001
Universidad Católica San Antonio de MurciaAcademic/Hospital1112018
Universidad de MurciaAcademic/Hospital1012011
University of CopenhagenAcademic/Hospital1012019
University of GranadaAcademic/Hospital1012011
University of GroningenAcademic/Hospital1112001
University of MalagaAcademic/Hospital1012016
University of ValenciaAcademic/Hospital1012011
13 organizations
Page 1 / 1